Advanced Colorectal Cancer Clinical Trial
Official title:
Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT
Primary Objective: The primary objective is to validate previously identified predictive/prognostic genomic DNA and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced CRC (a CRC) or metastatic CRC (mCRC). Secondary Objective: 1. To test the efficacy of bvz in combination with FOLFOX in patients with newly diagnosed advanced or metastatic K-ras mutant CRC and 2. To determine the progression free and overall survival of patients under first line FOLFOX + bvz in aCRC or mCRC.
Study Design: Type of Study: Exploratory, translational, multicenter and multinational Phase II study. Patient Population:All patients from the intent-to-treat population with aCRC or mCRC, (incurable with any conventional multimodality approach) and who fulfil all inclusion and exclusion criteria. Number of Patients: 224 Sample Type: Serial tissue and blood samples will be collected before (week 0), during (week 6, month 3 and 6) and at the end of treatment (month 12). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT06200363 -
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02923622 -
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
|
N/A | |
| Completed |
NCT01723969 -
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
|
||
| Active, not recruiting |
NCT00309179 -
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03699111 -
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
|
||
| Not yet recruiting |
NCT02826837 -
LEAC-102 for Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05077839 -
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
|
Phase 2 | |
| Recruiting |
NCT04324476 -
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06369259 -
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01271166 -
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00386828 -
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT04764006 -
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT04835324 -
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
|
||
| Active, not recruiting |
NCT02619435 -
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00498407 -
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05731336 -
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
|
||
| Active, not recruiting |
NCT04744831 -
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT03311750 -
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
|
Phase 2 |